Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 3/20 | 0.48 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.48 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.48 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.41 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.35 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27569047 | 0.95 | SLC6A12 (0.48) | SLC6A12SLC6A11SLC6A13GABRR1GABRR2 | |
| SCHEMBL19032979 | 0.91 | SLC6A12 (0.52) | SLC6A12SLC6A11SLC6A13GABRR1GABRR2 | |
| SCHEMBL1925986 | 0.88 | SLC6A12 (0.52) | SLC6A12SLC6A11SLC6A13GABRR1ALDH1A1 | |
| SCHEMBL29697589 | 0.85 | SLC6A12 (0.50) | SLC6A12SLC6A11SLC6A13GABRR1ALDH1A1 | |
| Bicarbonate SCHEMBL31059126 | 0.85 | GABRR1 (0.48) | SLC6A12SLC6A11SLC6A13GABRR1GABRR2 | |
| SCHEMBL11051978 | 0.83 | SLC6A12 (0.52) | SLC6A12SLC6A11SLC6A13GABRR1ALDH1A1 | |
| SCHEMBL2316031 | 0.79 | SLC6A12 (0.44) | SLC6A12SLC6A11SLC6A13GABRR1ALDH1A1 | |
| SCHEMBL14361052 | 0.78 | CA1 (0.52) | SLC6A12SLC6A11SLC6A13GRIN2DGRIN3B | |
| SCHEMBL7410374 | 0.77 | SLC6A12 (0.60) | SLC6A12SLC6A11SLC6A13GABRR1ALDH1A1 | |
| SCHEMBL3742078 | 0.77 | SLC6A12 (0.60) | SLC6A12SLC6A11SLC6A13GABRR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9226924-B2 | Methods of treating or preventing neuropathic pain | TORAY INDUSTRIES, INC. (JP) | 2016-01-05 | — | — | US | disclosed |
| US-20150105430-A1 | METHODS OF TREATING OR PREVENTING NEUROPATHIC PAIN | TORAY INDUSTREIS INC (JP) | 2015-04-16 | — | — | US | disclosed |
| EP-2599487-B1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR NEUROPATHIC PAIN | TORAY INDUSTRIES (JP) | 2015-04-01 | — | — | EP | disclosed |
| US-8957099-B2 | Treatment of ADHD | GOSFORTH CENTRE (HOLDINGS) PTY LTD. (AU) | 2015-02-17 | — | — | US | disclosed |
| US-8946267-B2 | Therapeutic agent or prophylactic agent for neuropathic pain | TORAY INDUSTRIES, INC. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20140080055-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140080055-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| EP-2599487-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR NEUROPATHIC PAIN | Toray Industries, Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20130131120-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR NEUROPATHIC PAIN | TORAY INDUSTRIES, INC. (JP) | 2013-05-23 | — | — | US | disclosed |
| US-20100087422-A1 | TREATMENT OF ADHD | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2010-04-08 | — | — | US | disclosed |
| EP-0224751-B1 | DIPHOSPHONIC-ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND MEDICINES CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1990-01-24 | — | — | EP | disclosed |
| US-4719203-A | CALCIUM METABOLISM DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1988-01-12 | — | — | US | disclosed |
| EP-0224751-A1 | Diphosphonic-acid derivatives, process for preparing them and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1987-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131120-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR NEUROPATHIC PAIN | CACNG2, TRPV1, CACNB2 | SLC6A12 624/4885SLC6A11 296/4885SLC6A13 299/4885 |
| US-20150105430-A1 | METHODS OF TREATING OR PREVENTING NEUROPATHIC PAIN | CACNB2, CACNG2, SCN2A | SLC6A12 367/4885SLC6A11 235/4885SLC6A13 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.